Perspectives for the use of collagen synthesis inhibitors as antifibrotic agents.
D003094:Collagen / Q000096:biosynthesis* / Q000235:genetics*; D003240:Connective Tissue Diseases / Q000188:drug therapy* / Q000378:metabolism; D005110:Extracellular Space / Q000378:metabolism; D005700:Galactosyltransferases / Q000378:metabolism; D005964:Glucosyltransferases / Q000378:metabolism; D006801:Humans; D011348:Procollagen N-Endopeptidase / Q000378:metabolism; D008240:Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase / Q000378:metabolism; D011393:Procollagen-Proline Dioxygenase / Q000378:metabolism; D008249:Protein-Lysine 6-Oxidase / Q000378:metabolism
D003094:Collagen; D011393:Procollagen-Proline Dioxygenase; D008240:Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase; D008249:Protein-Lysine 6-Oxidase; D005700:Galactosyltransferases; D005964:Glucosyltransferases; D011348:Procollagen N-Endopeptidase